Thomas Blaettler

Bitopertin in Negative Symptoms of Schizophrenia—Results From the Phase III FlashLyte and DayLyte Studies

Dragana Bugarski‐Kirola, Thomas Blaettler, Celso Arango et al. · Biological Psychiatry · 2016 · 137 citations

Daylyte Studies, Psychiatry, Psychotic Disorder +10

Safety and efficacy of olesoxime in patients with type 2 or non-ambulatory type 3 spinal muscular atrophy: a randomised, double-blind, placebo-controlled phase 2 trial

Enrico Bertini, Éric Dessaud, Eugenio Mercuri et al. · The Lancet Neurology · 2017 · 114 citations · Full text

Placebo-controlled Phase 2, Chronic Musculoskeletal Condition, Type 2 +6

Efficacy and safety of adjunctive bitopertin versus placebo in patients with suboptimally controlled symptoms of schizophrenia treated with antipsychotics: results from three phase 3, randomised, double-blind, parallel-group, placebo-controlled, multicentre studies in the SearchLyte clinical trial programme

Dragana Bugarski‐Kirola, Nakao Iwata, Snjezana Sameljak et al. · The Lancet Psychiatry · 2016 · 91 citations

Psychiatry, Psychotic Disorder, Psychotropic Medication +9

Efficacy and safety of arimoclomol in <scp>Niemann‐Pick</scp> disease type C: Results from a double‐blind, randomised, placebo‐controlled, multinational phase 2/3 trial of a novel treatment

Eugen Mengel, Marc C. Patterson, Rosalia Maria Da Riol et al. · Journal of Inherited Metabolic Disease · 2021 · 86 citations · Full text

Clinical Neurology, Cardiovascular Pharmacology, Neurochemical Biomarkers +22

Carboxy-Terminated Oligo(ethylene glycol)−Alkane Phosphate:  Synthesis and Self-Assembly on Titanium Oxide Surfaces

Mandy Gnauck, Evelin Jaehne, Thomas Blaettler et al. · Langmuir · 2006 · 63 citations